[1]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66:115-132. [2]Llovet JM, Burroughs A, Bruix J. Hepatocellular carcino-ma[J]. Lancet, 2003, 362: 1907-1917. [3]Liu Y, Zhang XR, Yang BC, et al. Demethylation-induced overexpression of Shc3 interacts with MVP and activates MEK/ERK independent of c-Raf[J]. Cancer Res, 2018, 78:2219-2233. [4]Miyake I, Ohira M, Nakagawara A, et al. Distinct role of ShcC docking protein in the differentiation of neuroblas-toma[J]. Oncogene, 2009, 28: 662-673. [5]Sun JX, Shi J, Li N, et al. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma[J]. Cancer Biol Med, 2016, 13:452-458. [6]Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma[J]. Hepatology, 1998, 27:951-958。 [7]张新然,强兆艳,庄昊,等. GDF15表达下调促进人胶质母细胞瘤细胞系U87MG增殖[J]. 基础医学与临床,2017,37:1557-1561. [8]De Falco V, Guarino V, Malorni L, et al. RAI (ShcC/N-Shc)-dependent reemitment of GAB1 to RET oncoproteins potentiates PI3-K signaling in thyroid tumors[J]. Oncogene, 2005, 24: 6303-6313. [9]Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activa-tion of Ras and Jak/Stat pathways in human HCC[J]. Gastroenterology, 2006, 130: 1117-1128. [10]Yang QS, Jiang LP, He CY, et al. Up-Regulation of microRNA-133a inhibits the MEK/ERK signaling pathway to promote cell apoptosis and enhance radio-sensitivity by targeting EGFR in esophageal cancer in vivo and in vitro[J]. J Cell Biochem, 2017, 118: 2625-2634. [11]Raoul JL, Adhoute X, Gilabert M, et al. How to assess the efficacy or failure of targeted therapy: deciding when to stop sorafenib in hepatocellular carcinoma[J]. World J Hepatol, 2016, 8: 1541-1546. [12]Mazzoccoli G, Miele L, Oben J, et al. Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of sorafenib[J]. Curr Drug Targets, 2016, 17:783-799. [13]Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66: 11851-11858. |